144896-92-4

Usage

Uses

Used in Pharmaceutical Industry:
(5S)-3,4,5,6-Tetrahydro-5-phenyl-4(H)-1,4-oxazin-2-one is used as a building block or intermediate in the organic synthesis of pharmaceuticals. Its specific structure and properties make it a valuable component in the development of complex molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (5S)-3,4,5,6-Tetrahydro-5-phenyl-4(H)-1,4-oxazin-2-one serves as a key intermediate for the production of various complex molecules. Its reactivity and structural features facilitate its involvement in a wide range of chemical reactions, contributing to the synthesis of diverse compounds with specific functions and applications.

InChI:InChI=1/C10H11NO2/c12-10-6-11-9(7-13-10)8-4-2-1-3-5-8/h1-5,9,11H,6-7H2/t9-/m1/s1

Upstream product

• 620-72-4 phenyl 2-bromoacetate 
• 20989-17-7 (2S)-2-phenylglycinol 
• 197167-72-9 (5S)-N-(benzyloxycarbonylaminomethyl)-5-phenylmorpholin-2-one 
• 491833-36-4 (S)-5-phenylmorpholin-2-one hydrochloride 

Downstream Products

• 134872-86-9 (4S,6aS,9aR,9bS)-4-Phenyl-hexahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-c][1,4]oxazine-1,7,9-trione 
• 139730-41-9 (4S,6aR,9aS,9bS)-8-((S)-2-Oxo-5-phenyl-morpholin-4-ylmethyl)-4-phenyl-hexahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-c][1,4]oxazine-1,7,9-trione 
• 197167-90-1 (4S,6aS,9aR,9bS)-8-Methyl-4-phenyl-hexahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-c][1,4]oxazine-1,7,9-trione 
• 197167-85-4 (4S,6aR,9aS,9bS)-8-Methyl-4-phenyl-hexahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-c][1,4]oxazine-1,7,9-trione 
• 134872-89-2 N-methyl 2(R),6(R),7(S),8(R) 2-phenyl-1-aza-4-oxa<4.3.0^1,6>bicyclononan-5-one-7,8-dicarboximide 
• 147406-85-7 (2R,6R,8S,12S)-1-aza-10-oxo-12-phenyltricyclo<6.4.0^1,8.0^2,6>dodecan-9-one 
• 144896-94-6 (2S,6S,7R,9S)-2,7,9-triphenyl-1-aza-4,8-dioxabicyclo[4.3.0^1,6]nonan-5-one 
• 172032-98-3 (4S,6S,7S,8R,8aS)-1-Oxo-4-phenyl-hexahydro-pyrrolo[2,1-c][1,4]oxazine-6,7,8-tricarboxylic acid 6-ethyl ester 7,8-dimethyl ester 
• 172139-89-8 (4S,6S,7S,8S,8aS)-1-Oxo-4-phenyl-hexahydro-pyrrolo[2,1-c][1,4]oxazine-6,7,8-tricarboxylic acid 6-ethyl ester 7,8-dimethyl ester 
• 182161-99-5 (5S,1'S)-N-[1'-(2-Furyl)-3'-phenylpropyl]-5-phenylmorpholin-2-one 
• 182161-97-3 (5S,1'S)-N-[1'-(2-Furyl)pentyl]-5-phenylmorpholin-2-one 
• 182162-03-4 (5S,1'S)-N-[1'-(2-furyl)-3',3'-dimethylbutyl]-5-phenylmorpholin-2-one 
• 182162-00-1 (5S,1'S)-N-[1'-(2-Furyl)-3',3'-dimethylbutyl]-5-phenylmorpholin-2-one 
• 182161-95-1 (5S,1'S)-N-[1'-(2-Furyl)butyl]-5-phenylmorpholin-2-one 

Relevant academic research and scientific papers

A mild approach to synthesise enantiopure glycine-derived 5-phenylthiomorpholinone

A seven-step synthetic route has been developed to access the labile C-3 unsubstituted 5-phenylthiomorpholinone system for the first time. The key step involved the nucleophilic ring opening of Boc-phenylmorpholinone to give the corresponding methyl ester. The sulfur introduction was accomplished through a Mitsunobu reaction to yield a thioacetate, which was then hydrolysed to provide the thiol acid. Cyclization of the thiol acid was achieved using DCC in the presence of DMAP, to give Boc-phenylthiomorpholinone and subsequent deprotection afforded the elusive C-3 unsubstituted 5-phenylthiomorpholinone.

Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors

Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Method for preparing tartrate EGS

The invention discloses a method for preparing tartrate EGS. The method comprises the following steps: (1) subjecting EGS-A4 represented by a formula shown in the description and trifluoroacetic acid to a reduction reaction in an inert atmosphere in the presence of a catalyst, so as to obtain EGS-SMA represented by a formula shown in the description after the reaction is complete, wherein the catalyst is Pd/C or the like; (2) preparing EGS-SMB represented by a formula shown in the description from EGS-B0 represented by a formula shown in the description, an acid binding agent and EGS-B0' represented by a formula shown in the description, then, subjecting the EGS-SMB to a reaction with the EGS-SMA so as to obtain EGS-API represented by a formula shown in the description, and then, subjecting the EGS-API to a reaction with L-tartaric acid, thereby obtaining the final product. The method can adapt to large-scale production processes and has the process characteristics of wide source, low cost and stable yield, and the yield of the obtained tartrate EGS is remarkably higher than that of the existing methods and can reach 95%, so that the method has an important application value.

IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT AND ITS SALTS

The present application relates to an improved process for the preparation of Eliglustat or its pharmaceutically acceptable salts thereof. Further relates to isolation of intermediates in the form of solid and their use for preparation of Eliglustat or its pharmaceutically acceptable salts thereof.

Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors

Disclosed is a novel enantiomeric synthesis cermamide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Carbamate derived stable precursors for generating chiral azomethine ylids under mild conditions.

We describe the evolution of stable azomethine ylid precursors which avoid the need for an aldehyde in the ylid generation step. tert-Butyl carbamate derivative (16) demonstrates comparable efficiency to the standard method of ylid generation and trapping, but permits use of milder conditions.

Development of a chiral stabilised azomethine ylid. A chiral relay system

The chiral, stabilised azomethine ylids (2) derived from (R)-2-phenylglycinol has been demonstrated to undergo enantioselective 1,3-dipolar cycloaddition reactions with a range of alkene and alkyne dipolarophiles.